Table 1.

Demographics, treatment history, and systemic disease associations in patients with autoimmune anterior uveitis treated with gevokizumab.

Pt	Demographics	Prior systemic treatments	Systemic associations	Concomitant Steroids
1	62 year-old white man	Oral corticosteroids, mycophenolate mofetil (off both at the time of enrollment)	None	None
2	50 year-old black woman	Oral corticosteroids (off prior to enrollment), methotrexate (last dose 15mg one month prior to enrollment)	Rheumatoid arthritis	Topical prednisolone acetate BID
3	34 year-old white woman	Intravenous corticosteroids (off prior to enrollment)	None	none
4	75 year-old black man	Indomethacin (50mg/day stopped ~4 months prior to enrollment)	None	Topical loteprednol TID
5	65 year-old white man	Ibuprofen (off prior to enrollment), methotrexate (last dose 10mg five days prior to enrollment), mycophenolate mofetil (1250mg BID stopped upon enrollment), infliximab (off prior to enrollment)	None	Topical loteprednol BID
6	61 year-old black man	Intravenous corticosteroids (off prior to enrollment)	None	None
7	81 year-old white man	Indomethacin (50mg TID stopped upon enrollment)	None	none
8	51 year-old white woman	Oral corticosteroids (prednisone 7.5mg/day), adalimumab (off for 3 months prior to enrollment), cyclosporine (off prior to enrollment), azathioprine (off prior to enrollment), methotrexate (off prior to enrollment), mycophenolate mofetil (off prior to enrollment), rituximab (off prior to enrollment)	Systemic lupus erythematosus, Sjogren’s syndrome	Oral prednisone (max dose 7.5mg/day), Topical loteprednol QID